Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 257
- Registration Number
- NCT05691712
- Locations
- 🇨🇳
The Second People's Hospital of Hefei, Hefei, Anhui, China
🇨🇳The First Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳The First Affiliated Hospital of Henan University of Science &Technology, LuoyangShi, Henan, China
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 795
- Registration Number
- NCT05662332
- Locations
- 🇺🇸
University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸Intend Research, LLC, Norman, Oklahoma, United States
🇺🇸Office 18, Pittsburgh, Pennsylvania, United States
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT05659537
- Locations
- 🇮🇳
Life Care Hospital and Research Centre, Bangalore, Karnataka, India
🇮🇳Akshay Hospital, Pune, Maharashtra, India
🇮🇳Virinchi Hospital, Hyderabad, Telangana, India
A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 456
- Registration Number
- NCT05644353
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸Qps-Mra, Llc, Miami, Florida, United States
A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT05630274
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 138
- Registration Number
- NCT05630196
- Locations
- 🇺🇸
Suncoast Research Group, Miami, Florida, United States
🇺🇸University of Miami Don Suffer Clinical Research Building, Miami, Florida, United States
🇺🇸New Horizon Research Center, Miami, Florida, United States
A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT05630287
- Locations
- 🇺🇸
LabCorp CRU, Inc., Madison, Wisconsin, United States
A Study of LY3305677 in Participants With Obesity Or Overweight
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT05623839
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸ICON Early Phase Services Lenexa Center, Salt Lake City, Utah, United States
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 147
- Registration Number
- NCT05620563
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸FutureSearch Trials of Neurology, Austin, Texas, United States
🇺🇸Northwest Clinical Research Center, Bellevue, Washington, United States
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 131
- Registration Number
- NCT05620576
- Locations
- 🇺🇸
Boston Clinical Trials, Boston, Massachusetts, United States
🇺🇸Suncoast Research Group, Miami, Florida, United States
🇺🇸Artemis Institute for Clinical Research, San Diego, California, United States